Yesterday, April 7, 2016, 40 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $213.84 to $15,000,000.00.

Highlighted Stocks Traded by Insiders:

Village Super Market (VLGEA) - FREE Research Report

Sumas John, who is Executive Vice President at Village Super Market, sold 4,000 shares at $24.15 on April 7, 2016. Following this transaction, the Executive Vice President owned 355,195 shares meaning that the stake was reduced by 1.11% with the 4,000-share transaction.

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 3,958 shares at $24.07 on April 7, 2016. Following this transaction, the Shareholder owned 671,748 shares meaning that the stake was reduced by 0.59% with the 3,958-share transaction.

The shares most recently traded at $23.55, down $0.52, or 2.21% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 17,687
  • 12-Week # shares sold: 59,632
  • 24-Week # shares sold: 130,714

The average volume for Village Super Market has been 33,700 shares per day over the past 30 days. Village Super Market has a market cap of $335.2 million and is part of the services sector and retail industry. Shares are down 10.02% year-to-date as of the close of trading on Wednesday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 4.22%. The company has a P/E ratio of 10.9. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aralez Pharmaceuticals (ARLZ) - FREE Research Report

Qlt Inc/Bc, who is 10% Owner at Aralez Pharmaceuticals, sold 2.4 million shares at $6.25 on April 7, 2016. Following this transaction, the 10% Owner owned 4.8 million shares meaning that the stake was reduced by 33.33% with the 2.4 million-share transaction.

The shares most recently traded at $4.01, down $2.24, or 55.86% since the insider transaction. Historical insider transactions for Aralez Pharmaceuticals go as follows:

  • 24-Week # shares bought: 1.0 million

The average volume for Aralez Pharmaceuticals has been 567,700 shares per day over the past 30 days. Aralez Pharmaceuticals has a market cap of $256.9 million and is part of the health care sector and drugs industry. Shares are down 36.9% year-to-date as of the close of trading on Wednesday.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. The company engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. Currently, there are 3 analysts who rate Aralez Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARLZ - FREE

TheStreet Quant Ratings rates Aralez Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Aralez Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

General Growth Properties (GGP) - FREE Research Report

Abu Dhabi Investment Authority, who is Shareholder at General Growth Properties, sold 22,400 shares at $29.07 on April 7, 2016. Following this transaction, the Shareholder owned 38.5 million shares meaning that the stake was reduced by 0.06% with the 22,400-share transaction.

The shares most recently traded at $28.76, down $0.31, or 1.09% since the insider transaction. Historical insider transactions for General Growth Properties go as follows:

  • 4-Week # shares bought: 19,500
  • 4-Week # shares sold: 6,051
  • 12-Week # shares bought: 19,500
  • 12-Week # shares sold: 6,051
  • 24-Week # shares bought: 19,500
  • 24-Week # shares sold: 175,052

The average volume for General Growth Properties has been 5.4 million shares per day over the past 30 days. General Growth Properties has a market cap of $25.6 billion and is part of the financial sector and real estate industry. Shares are up 6.39% year-to-date as of the close of trading on Wednesday.

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois. The stock currently has a dividend yield of 2.62%. The company has a P/E ratio of 20.3. Currently, there are 8 analysts who rate General Growth Properties a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GGP - FREE

TheStreet Quant Ratings rates General Growth Properties as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full General Growth Properties Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.